Gland Pharma’s Zoledronic Acid Injection, a treatment for malignancy-related bone issues, has received USFDA approval. This abbreviated new drug application (ANDA) approval enhances Gland Pharma's presence in the injectable market.
Cipla Limited has announced their “Win Over Weight” campaign on a national scale to create a new impression of obesity in India.
The CDSCO has issued a draft guidance document to help IVD medical device importers file import license applications online through the CDSCO portal and the National Single Window System, aiming to ensure faster and accurate approvals.
AstraZeneca and Daiichi Sankyo’s Datroway has received FDA Priority Review for unresectable or metastatic triple-negative breast cancer patients who are not eligible for immunotherapy, marking a key regulatory milestone.
AstraZeneca’s subcutaneous Saphnelo application rejected by FDA, delaying approval until 2026. However, it remains approved in the EU for treating lupus patients.
Novo Nordisk said today that its next-generation obesity drug CagriSema delivered better weight loss and blood sugar control than Wegovy in a late-stage diabetes trial, strengthening its pipeline in the fast-growing market.
Biocon Biologics has secured a credit rating upgrade from S&P Global Ratings to BB+, reflecting a simpler capital structure, improved financial discipline, and steady growth outlook in the global biosimilars market.
Piramal Pharma said it is seeing early signs of recovery in its CDMO business, driven by higher RFP activity and improving US biotech funding, even as inventory destocking continued to weigh on Q3FY26 results.c
Eli Lilly has entered a deal worth up to $1.12 billion with gene-editing firm Seamless Therapeutics, signaling a major push into advanced genetic treatments for hearing loss and rare diseases.
Zydus Lifesciences said its Ankleshwar manufacturing facility received three observations from the USFDA after a recent inspection, adding that none of the findings were linked to data integrity issues.